ALXN News and Press, Alexion Pharmaceuticals Inc. From 02/04/19

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q4 Non-GAAP EPS of $2.14 beats by $0.32 ; GAAP EPS of -$0.20 beats by $0.23 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase 4Q18 GAAP diluted EPS of $(0.20); non-GAAP diluted EPS of $2.14 2019 guidance: revenue $4,625 to $4,700 million; GAAP diluted EPS of $6.14 to $7.26; non-GAAP diluted EPS of $9....

Alexion Pharmaceuticals (NASDAQ: ALXN ) is scheduled to announce Q4 earnings results on Monday, February 4th, before market open. The consensus EPS Estimate is $1.82 (+23.0% Y/Y) and the consensus Revenue Estimate is $1.06B (+16.5% Y/Y). Over the last 2 years, ALXN has beaten EPS esti...

ALXN , AMG , BZH , CLX , SAIA , SYY For Seeking Alpha's full earnings season calendar, click here . More news on: Alexion Pharmaceuticals, Inc., Affiliated Managers Group, Beazer Homes USA, Inc., Earnings news and commentary, ,

Introduction to Alexion Pharmaceuticals Alexion Pharmaceuticals ( ALXN ) has been one of the greatest growth stories in the ultra-rare disease space over the past decade, with their blockbuster C5 inhibitor, Soliris, growing sales to nearly $4 billion in 2018. Although the company still m...

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will host an Investor Day on Wednesday, March 20, from 8:00am to 12:30pm ET. Alexion’s leadership team will highlight the continued advancement of the Company’s highly innovative pipeline which is focused o...

Rage was sometimes a useful ally in the heat of a fight, but it was a trickster. It made everything seem possible ." - Jonathan Maberry, Dust & Decay Alexion Pharmaceuticals ( ALXN ) was recommended as a Buy and put in the Holding Pen at The Biotech Forum just over a month. The ...

Nano cap Fortress Biotech (NASDAQ: FBIO ) is up  59%  premarket on average volume in response to a collaboration agreement between Caelum Biosciences , founded by FBIO, and Alexion Pharmaceuticals (NASDAQ: ALXN ) to develop CAEL-101, an amyloid fibril-targeted therapy for a rare...

- Collaboration provides opportunity to diversify Alexion’s clinical-stage rare hematology portfolio - - Caelum to receive up to $60 million for equity investment and option fee - - Alexion has option to acquire Caelum based on Phase 2 data - Alexion Pharmaceuticals,...

Fortress-founded Caelum Biosciences to receive $60 million in a strategic equity investment and option fee Alexion has option to acquire Caelum Biosciences based on Phase 2 data NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortressȁ...